Suliman AM, al-saber F, Hayes F, Fiad T, Culliton M, Cunningham S, McKenna TJ.
Dept. of Endocrinology and Diabetes Mellitus, St. Vincent’s Hospital, Elm Park, Dublin.
Ir Med J. 2000 May;93(3):74-6.
The charts of 184 patients with clinically significant hyperprolactinaemia who presented to a teaching hospital between 1978-1995 were reviewed, 158 (86%) females and 26 (14%) males. Hyperprolactinaemia was due to a microadenoma or was idiopathic in 36.4%, drug induced in 16%, associated with a macroadenoma in 12%, due to epilepsy in 7%, with other causes each contributing 5% or less. The presenting symptoms were amenorrhoea in 64%, galactorrhoea in 40.5%, infertility in 15%, visual field defect in 9%, with impotence in 30% and, gynaecomastia in 8% of men. One hundred and one patients were treated with bromocriptine (80%), surgery (35.4%) and radiotherapy (10.7%). Twenty-five percent of patients developed side-effects of bromocriptine for which cabergoline, a new long-lasting dopaminergic agonist, was successfully substituted. Presenting features responded to drug treatment in 70-80% of patients.
Keywords: Hyperprolactinaemia: analysis of presentation, diagnosis and treatment in the endocrine service of a general hospital.